Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Blue in the mouth

This article was originally published in The Tan Sheet

Executive Summary

McNeil re-launches its pre-brush mouth rinse Listerine Agent Cool Blue designed to help children pay more attention to brushing their teeth by temporarily tinting their teeth blue, the Morris Plains, N.J.-based division of Johnson & Johnson announces Sept. 29. The alcohol-free formula is for 6- to 12-year-olds and features an "enhanced preservative system" that includes potassium sorbate and cetylpyridinium chloride, a spokeswoman said. The re-launch comes after the product was recalled in April 2007 because "the preservative system was not adequate," J&J says (1"The Tan Sheet" April 16, 2007, In Brief). The new formula has "undergone rigorous quality standards" within FDA guidelines and meets "the highest safety standards," the spokeswoman added

You may also be interested in...



Listerine recall

McNeil announces April 11 a voluntary nationwide recall of approximately 4 mil. bottles of the Glacier Mint and Bubble Blast flavors of Listerine Agent Cool Blue Plaque-Detecting rinse. The Morris Plains, N.J.-based firm says "the preservative system in the product is not adequate against certain microorganisms." To date there have been no reports by consumers of adverse health events, McNeil says. The product launched in July 2006 as the first Listerine product marketed in the U.S. for children (1"The Tan Sheet" July 24, 2006, p. 14)...

Biogen Sees Improving Momentum In Slow Leqembi Launch

Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.

Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease

Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS102160

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel